These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1333 related articles for article (PubMed ID: 25473027)

  • 21. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
    Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
    Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.
    Pfaller MA; Castanheira M; Messer SA; Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2014 Jun; 79(2):198-204. PubMed ID: 24736096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
    Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
    BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Species distribution and antifungal susceptibility of invasive Candida isolates from Canadian hospitals: results of the CANWARD 2011-16 study.
    Fuller J; Dingle TC; Bull A; Shokoples S; Laverdière M; Baxter MR; Adam HJ; Karlowsky JA; Zhanel GG;
    J Antimicrob Chemother; 2019 Aug; 74(Suppl 4):iv48-iv54. PubMed ID: 31505645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
    Wang H; Xu YC; Hsueh PR
    Future Microbiol; 2016 Oct; 11():1461-1477. PubMed ID: 27750452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods for determining the susceptibilities of Candida isolates].
    Dalyan Cilo B; Topaç T; Ağca H; Sağlam S; Efe K; Ener B
    Mikrobiyol Bul; 2018 Jan; 52(1):35-48. PubMed ID: 29642828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro susceptibilities of bloodstream isolates of Candida spp.: results from a multicenter active surveillance program in Andalusia.
    Flórez C; Martín-Mazuelos E; Ruiz M; Cisneros JM; Herrero M; García MV; Márquez M; Porras J; Martín P; Gamero C; Castón JJ;
    Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):518-22. PubMed ID: 19477048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Six Antifungal Susceptibilities of 11
    Lee H; Choi SH; Oh J; Koo J; Lee HJ; Cho SI; Shin JH; Lee HK; Kim SY; Lee CH; Kim YR; Sohn YH; Kim WJ; Ryu SW; Sung GH; Kim J
    Microbiol Spectr; 2022 Apr; 10(2):e0125321. PubMed ID: 35384691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
    Fleck R; Dietz A; Hof H
    J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities.
    Wisplinghoff H; Ebbers J; Geurtz L; Stefanik D; Major Y; Edmond MB; Wenzel RP; Seifert H
    Int J Antimicrob Agents; 2014 Jan; 43(1):78-81. PubMed ID: 24182454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [One-Year Candida Data of the Central Mycology Laboratory: Which Sample, Which Species, How Resistant?].
    Turan D; Aksaray S
    Mikrobiyol Bul; 2022 Jul; 56(3):493-505. PubMed ID: 35960240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antifungal susceptibility testing results of New Zealand yeast isolates, 2001-2015: Impact of recent CLSI breakpoints and epidemiological cut-off values for Candida and other yeast species.
    Morris AJ; Rogers K; McKinney WP; Roberts SA; Freeman JT
    J Glob Antimicrob Resist; 2018 Sep; 14():72-77. PubMed ID: 29486358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distribution and antifungal susceptibility of Candida species causing nosocomial candiduria.
    Ozhak-Baysan B; Ogunc D; Colak D; Ongut G; Donmez L; Vural T; Gunseren F
    Med Mycol; 2012 Jul; 50(5):529-32. PubMed ID: 21988703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.
    Wang H; Xiao M; Chen SC; Kong F; Sun ZY; Liao K; Lu J; Shao HF; Yan Y; Fan H; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Xu YC
    J Clin Microbiol; 2012 Dec; 50(12):3952-9. PubMed ID: 23035204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
    Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study.
    Mokaddas EM; Al-Sweih NA; Khan ZU
    J Med Microbiol; 2007 Feb; 56(Pt 2):255-259. PubMed ID: 17244809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
    Panizo MM; Reviákina V; Dolande M; Selgrad S
    Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
    Drago M; Scaltrito MM; Morace G;
    Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):619-24. PubMed ID: 15258831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.